Logo image of OABI

OMNIAB INC (OABI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OABI - US68218J1034 - Common Stock

1.85 USD
-0.01 (-0.54%)
Last: 12/31/2025, 8:20:23 PM
1.82 USD
-0.03 (-1.62%)
After Hours: 12/31/2025, 8:20:23 PM
Fundamental Rating

4

Overall OABI gets a fundamental rating of 4 out of 10. We evaluated OABI against 57 industry peers in the Life Sciences Tools & Services industry. OABI has a great financial health rating, but its profitability evaluates not so good. OABI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year OABI has reported negative net income.
In the past year OABI has reported a negative cash flow from operations.
In the past 5 years OABI always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: OABI reported negative operating cash flow in multiple years.
OABI Yearly Net Income VS EBIT VS OCF VS FCFOABI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

OABI has a Return On Assets of -20.54%. This is in the lower half of the industry: OABI underperforms 64.91% of its industry peers.
The Return On Equity of OABI (-22.92%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -20.54%
ROE -22.92%
ROIC N/A
ROA(3y)-12.62%
ROA(5y)-10.53%
ROE(3y)-14.73%
ROE(5y)-12.64%
ROIC(3y)N/A
ROIC(5y)N/A
OABI Yearly ROA, ROE, ROICOABI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OABI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OABI Yearly Profit, Operating, Gross MarginsOABI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

8

2. Health

2.1 Basic Checks

OABI does not have a ROIC to compare to the WACC, probably because it is not profitable.
OABI has more shares outstanding than it did 1 year ago.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
OABI Yearly Shares OutstandingOABI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OABI Yearly Total Debt VS Total AssetsOABI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 3.77 indicates that OABI is not in any danger for bankruptcy at the moment.
OABI's Altman-Z score of 3.77 is fine compared to the rest of the industry. OABI outperforms 71.93% of its industry peers.
OABI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.77
ROIC/WACCN/A
WACC10.84%
OABI Yearly LT Debt VS Equity VS FCFOABI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.00 indicates that OABI has no problem at all paying its short term obligations.
OABI has a Current ratio of 5.00. This is in the better half of the industry: OABI outperforms 78.95% of its industry peers.
A Quick Ratio of 4.96 indicates that OABI has no problem at all paying its short term obligations.
OABI's Quick ratio of 4.96 is amongst the best of the industry. OABI outperforms 85.96% of its industry peers.
Industry RankSector Rank
Current Ratio 5
Quick Ratio 4.96
OABI Yearly Current Assets VS Current LiabilitesOABI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.45% over the past year.
The Revenue has been growing slightly by 3.36% in the past year.
The Revenue has been growing slightly by 7.57% on average over the past years.
EPS 1Y (TTM)6.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-8.76%
Revenue growth 5Y7.57%
Sales Q2Q%-46.33%

3.2 Future

OABI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.16% yearly.
Based on estimates for the next years, OABI will show a very strong growth in Revenue. The Revenue will grow by 25.08% on average per year.
EPS Next Y7.71%
EPS Next 2Y15.26%
EPS Next 3Y13.43%
EPS Next 5Y13.16%
Revenue Next Year-25.22%
Revenue Next 2Y11.48%
Revenue Next 3Y20.43%
Revenue Next 5Y25.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OABI Yearly Revenue VS EstimatesOABI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
OABI Yearly EPS VS EstimatesOABI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.2 -0.4 -0.6

0

4. Valuation

4.1 Price/Earnings Ratio

OABI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OABI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OABI Price Earnings VS Forward Price EarningsOABI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OABI Per share dataOABI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

OABI's earnings are expected to grow with 13.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.26%
EPS Next 3Y13.43%

0

5. Dividend

5.1 Amount

OABI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

OMNIAB INC

NASDAQ:OABI (12/31/2025, 8:20:23 PM)

After market: 1.82 -0.03 (-1.62%)

1.85

-0.01 (-0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners44.23%
Inst Owner ChangeN/A
Ins Owners5.68%
Ins Owner Change8.1%
Market Cap266.33M
Revenue(TTM)21.09M
Net Income(TTM)-63.60M
Analysts84.62
Price Target7.48 (304.32%)
Short Float %4.8%
Short Ratio8.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.16%
Min EPS beat(2)1.96%
Max EPS beat(2)4.35%
EPS beat(4)2
Avg EPS beat(4)0.06%
Min EPS beat(4)-4.45%
Max EPS beat(4)4.35%
EPS beat(8)4
Avg EPS beat(8)0.62%
EPS beat(12)5
Avg EPS beat(12)5.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-44.74%
Min Revenue beat(2)-61.11%
Max Revenue beat(2)-28.38%
Revenue beat(4)1
Avg Revenue beat(4)-23.54%
Min Revenue beat(4)-61.11%
Max Revenue beat(4)4.57%
Revenue beat(8)2
Avg Revenue beat(8)-23.65%
Revenue beat(12)3
Avg Revenue beat(12)-20.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.87%
EPS NY rev (1m)6.4%
EPS NY rev (3m)7.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.15%
Revenue NY rev (1m)-11.11%
Revenue NY rev (3m)-11.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.63
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.15
BVpS1.93
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.54%
ROE -22.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.62%
ROA(5y)-10.53%
ROE(3y)-14.73%
ROE(5y)-12.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.75%
Cap/Sales 2.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5
Quick Ratio 4.96
Altman-Z 3.77
F-Score5
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)36.82%
Cap/Depr(5y)29.77%
Cap/Sales(3y)13.66%
Cap/Sales(5y)12.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y7.71%
EPS Next 2Y15.26%
EPS Next 3Y13.43%
EPS Next 5Y13.16%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-8.76%
Revenue growth 5Y7.57%
Sales Q2Q%-46.33%
Revenue Next Year-25.22%
Revenue Next 2Y11.48%
Revenue Next 3Y20.43%
Revenue Next 5Y25.08%
EBIT growth 1Y9.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.17%
EBIT Next 3Y13.11%
EBIT Next 5YN/A
FCF growth 1Y-1479.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-905.12%
OCF growth 3YN/A
OCF growth 5YN/A

OMNIAB INC / OABI FAQ

What is the ChartMill fundamental rating of OMNIAB INC (OABI) stock?

ChartMill assigns a fundamental rating of 4 / 10 to OABI.


Can you provide the valuation status for OMNIAB INC?

ChartMill assigns a valuation rating of 0 / 10 to OMNIAB INC (OABI). This can be considered as Overvalued.


How profitable is OMNIAB INC (OABI) stock?

OMNIAB INC (OABI) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for OABI stock?

The Earnings per Share (EPS) of OMNIAB INC (OABI) is expected to grow by 7.71% in the next year.